News | January 21, 2010

Interventional Treatment Short-Circuits Hypertension

The Symplicity Catheter System manufactured by Ardian Inc. delivers radio frequency (RF) energy from within the renal artery to block conduction in the surrounding renal nerves.


January 21, 2010 – A new minimally invasive therapy using radiofrequency ablation to short-circuit nerves in the kidney arteries shows promise in treating uncontrolled hypertension. The research was presented this week at the International Symposium on Endovascular Therapy (ISET).

In a study of 70 patients, who had uncontrolled hypertension despite taking three or more blood pressure medications, underwent the procedure, called sympathetic renal denervation (RDN). One month after treatment, the average decrease in systolic blood pressure was 18 mmHg and in diastolic blood pressure was 11 mmHg. Blood pressure continued to improve, and the 34 patients who have reached 12-month follow-up had an average decrease in systolic blood pressure of 27 mmHg and in diastolic blood pressure of 11 mmHg.

“This treatment may help people who have the worst of the worst disease – who have hypertension that medications just can’t control and who are most likely to suffer from stroke and heart disease,” said Krishna Rocha-Singh, M.D., medical director of Prairie Vascular Institute, Springfield, Illinois, who is presenting results at ISET. “There are broader implications of this procedure, such as the possibility of using it to address other conditions, such as chronic kidney disease and heart failure. Another hope is that we eventually may be able to use this therapy to help patients with mild to moderate hypertension, without the use of drug therapy.”

Blood pressure is controlled by a combination of nerve signals and hormonal interactions between the brain, heart, blood vessels and kidneys. Hyperactive nerve signals from the kidneys may be a main cause of hypertension in many people. The nerves traveling to the kidneys are a key final common pathway needed to raise blood pressure. RDN treatment is used to interrupt these hyperactive signals between the kidney and the brain, leading to lower blood pressure. In the procedure, a tiny incision is made in the groin artery and a thin tube (catheter) with an electrode on the tip is inserted and advanced to the kidney arteries. The electrode is placed at up to six points along each artery, and low-dose radiofrequency energy is delivered to disable the surrounding nerves.

The kidneys play a central role in the long-term control of blood pressure, so the kidney is a major target of medicines used to control hypertension. However, more than a third of the 75 million Americans with hypertension are unable to control the condition, despite taking medication.

For more information: www.ISET.org


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now